Nutranomics Announces Glucozyme Human Clinical Study Results Nearing Release

07 Oct 2013 --- Nutranomics, Inc. is pleased to announce that the results of human patient clinical studies undertaken by the Company regarding Glucozyme are nearing a public release date. Glucozyme is a proprietary nutritional supplement being developed by Nutranomics that has been shown to aid in the processing of sugars to maintain proper glucose and insulin levels in patients with diabetes and pre-diabetes.

Following the conclusion of the latest Glucozyme clinical studies conducted in Japan and Mexico, the resulting new patient data was compiled and compared with previous testing conducted in North America prior to submission for product approval and distribution in several world markets.

"As with all Nutranomics proprietary formulas, Glucozyme is being thoroughly tested for safety and effectiveness prior to release to distributors and the public. In the case of Glucozyme, we will have three separate clinical studies conducted independently of each other in three different countries to support the science behind the product," commented Dr. Tracy Gibbs, CEO of Nutranomics.  "Diabetes and pre-diabetes have reached epidemic proportions affecting almost 350 million people worldwide.  We all know someone afflicted by diabetes or at serious risk.  Following the successful release of results from the clinical studies, Glucozyme will be one step closer to helping patients manage their glucose levels more effectively and potentially prevent diabetes from impacting their lives dramatically."

Nutranomics anticipates that data compilation and analysis from the Glucozyme clinical studies will be made available within the next 2-3 weeks at which time the Company expects to release an additional statement.